ALL-Hematotox的开发:预测B细胞急性淋巴细胞白血病CAR-T治疗后血液毒性
在156例复发/难治性B细胞急性淋巴细胞白血病儿童和年轻成人中,重度中性粒细胞减少中位持续13天,53%发生≥3级ICAHT;CAR-HT模型区分能力有限,基于骨髓疾病负荷替代铁蛋白构建的ALL-HT评分与重度迁延性中性粒细胞减少相关(AUC=0.84),并在2个独立队列中验证。
要点
- B-ALL患者CAR-T后重度中性粒细胞减少中位持续13天(95%CI 10-16天),53%发生≥3级ICAHT。
- CAR-HT模型在B-ALL中近90%被归为高危,区分能力有限。
- ALL-HT评分以骨髓疾病负荷替代铁蛋白,AUC=0.84,并在2个独立队列中验证。
核心结论
- ALL-HT评分改进了广泛接受的CAR-T输注后血液毒性预测模型,适用于B-ALL。
研究设计与样本
- 研究纳入156例复发/难治性B-ALL儿童和年轻成人,描述ICAHT并评估CAR-HT模型的预测能力,进而开发ALL-HT评分并在2个独立队列中验证。
主要发现
- 重度中性粒细胞减少(ANC<500/μL)中位持续13天(95%CI 10-16天),83例(53%)发生≥3级ICAHT。
- 应用CAR-HT模型,近90%患者被归为高危,区分能力有限。
- 骨髓疾病负荷与输注后中性粒细胞减少相关(r=0.64,P<.0001)。
- ALL-HT评分与重度迁延性中性粒细胞减少相关(AUC=0.84,P<.0001)。
- ALL-HT高危组(47%)累积中性粒细胞减少天数更多(26天 vs 4天;P<.0001),完全缓解率更低(88% vs 98%;P=.03),中位总生存更短(9.8个月 vs 24个月;log-rank P=.0002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune effector cell-associated hematotoxicity (ICAHT) is a major B-cell targeted chimeric antigen receptor (CAR) T-cell related toxicity. Although ICAHT incidence and severity is documented in large B-cell lymphoma (LBCL), mantle cell lymphoma (MCL), and multiple myeloma (MM), ICAHT has not been described in B-cell acute lymphoblastic leukemia (B-ALL). Similarly, the CAR-HEMATOTOX (CAR-HT) model, designed to predict severe prolonged neutropenia (≥14 days of absolute neutrophil count [ANC] <500/μL), has been validated in LBCL, MCL, and MM, but not in B-ALL. As B-ALL bone marrow (BM) infiltration can impact cytopenias, we sought to describe ICAHT and assess CAR-HT for predicting hematotoxicity in B-ALL. In a cohort of 156 children and young adults with relapsed/refractory B-ALL, the median duration of severe neutropenia (ANC <500/μL) was 13 days (95% confidence interval, 10-16 days), with 83 (53%) experiencing grade ≥3 ICAHT. Applying CAR-HT, nearly 90% were classified as high risk, demonstrating limited discriminative power and prompting further development. Using the association identified between BM disease burden and postinfusion neutropenia (r = 0.64, P < .0001), we developed the ALL-Hematotox (ALL-HT) score, which substitutes BM disease burden for ferritin in CAR-HT. The ALL-HT score associated with severe prolonged neutropenia (area under the curve = 0.84, P < .0001), and appropriately discriminated high-risk patients (47%) who had more cumulative days of neutropenia (26 vs 4 days; P < .0001), fewer rates of complete response (88% vs 98%; P = .03), and shorter median overall survival (9.8 vs 24 months; log-rank P = .0002). ALL-HT was also validated in 2 independent cohorts. The ALL-HT score refines a widely accepted predictive model of postinfusion hematotoxicity, which is applicable in B-ALL.
引用
- Nair MS, Silbert SK, Rejeski K, et al. Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia. Blood. 2025. PMID: 39561284. doi:10.1182/blood.2024025910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。